Telomir net loss narrows to $1.72 million in Q2 FY26; revenue flat at no revenue
TELO•Q2 FY26 results and cash position
- Telomir Pharmaceuticals posted a net loss of $1.72 million for the quarter ended June 30, 2026, narrowing from $5.07 million.
- Operating costs fell to $1.76 million from $5.07 million, driven by general and administrative expense dropping to $1.32 million from $5.03 million.
- Research and development expense rose to $444,674 from $42,839 on higher pre-clinical research and R&D consultant costs.
- Cash and cash equivalents totaled about $5.2 million at June 30, 2026; operating cash outflow was $2.79 million for the six months.
- The FDA cleared the IND to start a Telomir-Zn trial in advanced or metastatic triple-negative breast cancer; cash is expected to fund operations through Q1 2027.
